Navigation Links
Genetics Should Decide Warfarin Dose, Study Reiterates
Date:3/20/2009

What works for some people might be dangerous for others,,

FRIDAY, March 20 (HealthDay News) -- Researchers have confirmed previously reported genetic factors that may help doctors more accurately prescribe the proper dosage of the blood thinner warfarin to people at high risk of cardiovascular problems.

According to U.S. Food and Drug Administration estimates, about 2 million Americans use the anticoagulant medication to prevent blood clots and reduce the likelihood of a stroke, pulmonary embolism or heart attack.

Though the drug can be very effective, the optimal therapeutic dosage varies as much as 20-fold among individuals, with too high a dose risking severe bleeding and too small a dose failing to protect against the original cardiovascular worry. Trial and error followed by frequent monitoring of blood levels have been the common method of determining the proper dose for a given person.

Researchers from Sweden and the United Kingdom, studying the genetic makeup of more than 1,000 warfarin users, reported finding three genes -- VKORC1, CYP2C9 and CYP4F2 -- with common variants that explain more than 40 percent of the variability in optimal dosing levels. VKORC1, which affects the liver's ability to use and excrete warfarin, and CYP2C9, which helps with the essential blot-clotting vitamin K, were found to be responsible for the vast majority of the variability, according to the study. The findings were to be published March 20 in PLoS Genetics.

The finding appears to support a study in the Feb. 19 issue of the New England Journal of Medicine. In that report, American researchers collected data -- including the VKORC1 and CYP2C9 variants -- from more than 4,000 people taking warfarin and created an algorithm that had a high rate of success predicting the ideal dose of the drug.

More information

The U.S. National Library of Medicine has more about warfarin.



-- Kevin McKeever



SOURCES: PLoS Genetics, news release, March 19, 2009; New England Journal of Medicine, Feb. 19, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Genetics Hold Promise, Challenges for Cancer Care
2. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
3. Salugen to Present Research on Generational Associations of Reward Deficiency Syndrome at XVth World Congress on Psychiatric Genetics
4. Obesity genetics
5. The genetics of MLL leukemogenesis
6. Vanda Pharmaceuticals to Present New Data on Iloperidone at the 2007 American Society of Human Genetics Annual Meeting
7. Clarient Names Michele Hibbard, Ph.D. Director of Genetics
8. Response Genetics Announces Presentation/Webcast at BIOCOM Investor Conference
9. Interleukin Genetics to Host Third Quarter 2007 Financial Results Conference Call November 7
10. Response Genetics to Announce Third Quarter 2007 Financial Results on Wednesday, November 14, 2007
11. Response Genetics Reports Third Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Genetics Should Decide Warfarin Dose, Study Reiterates
(Date:2/7/2016)... (PRWEB) , ... February 07, 2016 , ... ... prolapse with the latest techniques and the most minimally invasive approaches. , Women ... prolapse, particularly after menopause. Other risk factors include surgery to the pelvic floor, ...
(Date:2/7/2016)... , ... February 07, 2016 , ... ... program. MyDecision™ empowers employers and organizations with the tools and information to lower ... three elements to cut the cost of providing employee healthcare benefits by as ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... 5000 PERIOPERATIVE NURSES EXPECTED AT AORN SURGICAL CONFERENCE & EXPO , WHAT: ... world with an estimated 5000 perioperative nurses in attendance to study the ...
(Date:2/6/2016)... ... February 06, 2016 , ... With the FCPX ... warm color grades to their footage. A LUT is a Lookup Table that contains ... the corresponding color indicated by the table. By manipulating each pixel, LUT's can change ...
(Date:2/6/2016)... ... 06, 2016 , ... Research has shown that building shame ... frequency and level of relapse. , At the 2016 iaedp Symposium, ... explore the critical tasks of the recovery phase and beyond including relapse prevention ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... 2016  Syneron Medical Ltd. (NASDAQ: ELOS ... today that William Griffing , Chief Executive ... to participate in the Leerink Partners 5 th ... 2016 in New York City ... meet with the Mr. Griffing and will include ...
(Date:2/5/2016)... Feb. 5, 2016  As people age, it is ... of recommended screenings and tests that are linked with ... However, for the majority of aging individuals, hearing health ... For the 37.5 million American adults who report some ... to make hearing health a 2016 healthy aging priority.[1] ...
(Date:2/5/2016)...  Aralez Pharmaceuticals Inc. ("Aralez") today announced the completion ... Pharmaceuticals Canada Inc. ("Tribute") following approval of the transaction ... combined company will operate under Aralez Pharmaceuticals Inc. ("Aralez"), ... Canada , Ireland ... the terms of the Agreement and Plan of Merger ...
Breaking Medicine Technology: